The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Management of high-risk and frail patients, MRD & teclistamab
In this discussion, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, and Rakesh Popat, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, comment on the identification and management of patients with newly diagnosed high-risk multiple myeloma, highlighting data from various UK clinical trials. Dr Pawlyn and Dr Popat then discuss the prognostic value of MRD, debating the different techniques and thresholds currently used in clinical practice. Finally, Dr Pawlyn and Dr Popat talk on the optimal management of frail patients with multiple myeloma and comment on the recent approval of teclistamab by the European Commission, questioning how to best deliver this agent. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
